Needham & Company Raises Price Target on Xactly Corporation (XTLY) Following Solid 1Q Results

UBS Remains Neutral on Xactly Corporation (XTLY) Following 1Q Beat and Raise

UBS reiterated a Neutral rating on Xactly Corporation (NYSE: XTLY), and raised the price target to $11.00 (from $7.00), following the company's 1Q earnings report. XTLY reported revenues of $23.3M, beating the Street's $22.0M estimate. EPS of -$0.09 also came in ahead of the Street (-$0.15).

Analyst Brent Thill commented, "XTLY's FQ1 showed consistency, with revs ($23.3M vs. Street $22.0M)... More

After-Hours Stock Movers 06/06: (SRPT) (UNFI) (ZG) Higher; (DRYS) (MSTX) (ALXN) Lower (more...)

Today's After-Hours Movers:

Sarepta Therapeutics (NASDAQ: SRPT) 26.7% HIGHER; announced that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.

DryShips (NASDAQ:... More

Xactly Corp. (XTLY) Reports In-Line Q1 EPS

Xactly Corp. (NYSE: XTLY) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $23.3 million versus the consensus estimate of $22.04 million.

GUIDANCE:

Xactly Corp. sees Q2 2017 EPS of ($0.15)-($0.13), versus the consensus of... More

Trading Radar for 6/6: Layne Christensen (LAYN), Xcerra (XCRA), United Natural Foods (UNFI), Thor (THO) Report

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:

Earnings:

Ability, Inc. (Nasdaq: ABIL) - consensus EPS $0.03
Xcerra (Nasdaq: XCRA) - consensus EPS... More